Pare previously served as VP and general manager of international at the company. The chief commercial officer role was a newly created position within T2 Biosystems.
“I am delighted to appoint Tony as our chief commercial offer and look forward to working with him to expand our commercial success,” CEO John Sperzel said in a news release. “In his previous role as VP and general manager – international, he led the expansion and growth of our international business and I am confident that he will serve as a driving force of success and rapid growth in the company’s next phase.”
Prior to joining T2 Biosystems, Pare spent 18 years at Haemonetics where he held a number of leadership positions, including a commercial leader and VP of business development, mergers and acquisitions. He also served as chief commercial officer of Hemanext for three years.
“As someone who has spent his life’s work in the medical device and diagnostics industry, I recognize the unique clinical value T2 Biosystems’ technology brings to patients suspected of sepsis, and am thrilled to have the opportunity to serve as chief commercial officer for the company and help to lead further expansion and utilization of our innovative rapid diagnostics,” Pare said. “With T2 Biosystems’s technology, clinicians can rely less on empiric therapy and apply more targeted treatment by knowing the pathogen in a patient’s bloodstream in a matter of hours instead of days. I look forward to working with our sales force and distribution partners to help get these groundbreaking diagnostics into more hospitals where they can help benefit patients.”